
X
FDA panel backs J&J’s potential depression blockbuster
https://pharmaphorum.com/news/fda-panel-backs-jjs-potential-depression-blockbuster/
Drug targets 30% of people who don’t respond to approved treatments
Drug missed efficacy endpoint in older population
Companies want Vraylar as option bipolar depression
App corresponds with standard cognitive and patient-reported assessment measures.